• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Inogen Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    3/30/26 5:32:03 PM ET
    $INGN
    Industrial Specialties
    Health Care
    Get the next $INGN alert in real time by email
    8-K
    false0001294133Inogen Inc00012941332026-03-242026-03-24

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 24, 2026

     

     

    INOGEN, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-36309

    33-0989359

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    500 Cummings Center

    Suite 2800

     

    Beverly, Massachusetts

     

    01915

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (805) 562-0500

     

     

    859 Ward Drive

    Goleta, California 93111

    (Former address)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value

     

    INGN

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Appointment of Chief Financial Officer

    On March 24, 2026, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Jason Richardson to serve as Executive Vice President, Chief Financial Officer and Treasurer (“CFO”) of the Company, effective April 6, 2026.

    Most recently, Mr. Richardson, 49, served as Chief Financial Officer and Vice President of the Health System and Technologies Segment of Baxter International Inc. (NYSE: BAX) since 2023. He also served as Vice President of Finance Americas and Global Business Units at Baxter from 2021 to 2023. Prior to Baxter’s acquisition of Hillrom, Mr. Richardson held a variety of senior finance leadership roles at Hillrom, including over its Respiratory Health business. Mr. Richardson received a bachelor’s degree in accounting and finance from Indiana University.

    On March 24, 2026, the Board, upon the recommendation of the Compensation Committee of the Board, approved, and the Company entered into, an employment and severance agreement with Mr. Richardson (the “employment agreement”), effective April 6, 2026 (the “Effective Date”). Mr. Richardson’s employment under the employment agreement will begin on the Effective Date and is at will and may be terminated at any time by the Company or by Mr. Richardson. Pursuant to the employment agreement, Mr. Richardson will receive an annual base salary of $525,000 and a target annual performance bonus opportunity of seventy percent (70%) of his annual base salary. The employment agreement provides for (i) a cash sign-on bonus of $50,000, which is repayable on a pro-rata basis if, prior to the second anniversary of the Effective Date, Mr. Richardson’s employment is terminated by the Company for cause or Mr. Richardson resigns without good reason (in each case as defined in the employment agreement), and (ii) a cash retention bonus of $50,000, which is payable on the first anniversary of the Effective Date.

    The employment agreement also provides for equity awards of restricted stock units covering an aggregate of 200,000 shares of the Company’s common stock, comprised of (i) 100,000 time-based restricted stock units (“RSUs”) and (ii) 100,000 performance-based restricted stock units (“PSUs”); provided that overachievement of the performance goals may result in Mr. Richardson receiving up to a maximum of 150,000 PSUs. Subject to Mr. Richardson’s continued service with the Company, one-third of the RSUs will vest annually over three years. Subject to Mr. Richardson’s continued service with the Company, the PSUs will vest based on the Company’s achievement of specified performance goals set forth in the 2026 equity awards that apply to the performance-based awards that were granted to the Company's similarly situated executives.

    The RSUs and PSUs will be granted on the Effective Date and are each subject to the terms and conditions of the applicable award agreements. The RSUs and PSUs will be granted as independent inducement awards outside of the terms of the Company’s existing equity incentive plans in compliance with an exemption from Nasdaq’s shareholder approval requirements under Nasdaq Stock Market Rule 5635(c)(4).

    The employment agreement also provides that Mr. Richardson will be eligible to receive equity awards pursuant to any plans or arrangements that the Company may have in effect from time to time, and as approved by the Board or the Compensation Committee.

    Mr. Richardson’s employment agreement also provides that if, outside of the period beginning on the date three months before, and ending on the date 12 months following, a change of control (as defined in the employment agreement) (such period, the “change of control period”), his employment with the Company is terminated by the Company without cause (excluding by reason of death or disability) or he resigns for good reason, he will be eligible to receive the following severance benefits:

    •
    continued payment of his base salary for a period of 12 months following his termination date; and
    •
    for up to 12 months under the Consolidated Omnibus Budget Reconciliation Act of 1986 ("COBRA") following his termination date, he and his eligible dependents will only be required to pay the portion of the costs of medical benefits as he was required to pay as of the date of his termination, or he will receive taxable monthly payments for the equivalent period in the event the Company determines that the COBRA subsidy could violate applicable law (the “COBRA Benefits”).

    The employment agreement further provides that if, during the change of control period, Mr. Richardson’s employment with the Company is terminated by the Company without cause (excluding by reason of death or disability) or he resigns for good reason, he will be eligible to receive the same severance benefits described above, except that he will receive continued payment of his base salary for a period of 24 months following his termination date.

    Mr. Richardson’s receipt of the severance benefits described above is conditioned on his timely signing and not revoking a release of claims, resigning all directorships, committee memberships or any other positions he holds with the Company, and continuing to comply with certain covenants in the employment agreement and in his at-will employment, confidential information, invention assignment, and arbitration agreement with the Company.

    If any of the payments provided for under the employment agreement or otherwise payable to Mr. Richardson would constitute “parachute payments” within the meaning of Section 280G of the Internal Revenue Code and would be subject to the related excise tax under Section 4999 of the Internal Revenue Code, then he will be entitled to receive either full payment of benefits or such lesser amount that would result in no portion of the benefits being subject to the excise tax, whichever results in the greater amount of after-tax benefits to him.


    The summary of Mr. Richardson’s employment and severance agreement set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the employment and severance agreement, which is filed with this Current Report on Form 8-K as Exhibit 10.1 and incorporated by reference herein.

    In addition, Inogen has entered into its standard form of indemnification agreement with Mr. Richardson. The form indemnification agreement was filed with the Securities and Exchange Commission on November 27, 2013 as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 and is incorporated herein by reference. Mr. Richardson has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor are any such transactions currently proposed. There is no arrangement or understanding between Mr. Richardson or any other person pursuant to which Mr. Richardson was selected as an officer. There are no family relationships between Mr. Richardson and any of the Company’s directors or executive officers.

    Separation of Chief Financial Officer

    On March 24, 2026, in connection with the appointment of Mr. Richardson as the Company’s new Chief Financial Officer, Michael Bourque, Executive Vice President, Finance, Chief Financial Officer, and Treasurer, notified the Company of his intention to step down as an officer of the Company effective upon the date Mr. Richardson commences employment with the Company. Mr. Bourque will remain employed by the Company as a [Senior Advisor] and will provide transition services to the Company through no later than June 30, 2026. Mr. Bourque’s decision to step down as the Company’s Chief Financial Officer was not related to any disagreements with the Company or its management on any matters relating to the Company’s operations, policies, or practices.

    Item 7.01. Regulation FD Disclosure.

    On March 30, 2026, the Company issued a press release announcing the Chief Financial Officer appointment and transition described in this Current Report on Form 8-K, as well as certain other leadership appointments. A copy of the press release is furnished herewith as Exhibit 99.1.

    The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

     

     Description

    10.1

     

    Employment and Severance Agreement by and between the Company and Jason Richardson, effective as of April 6, 2026

    99.1

    Press Release dated March 30, 2026.

    104

    The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    INOGEN, INC.

     

     

     

     

    Date:

    March 30, 2026

    By:

    /s/ Kevin P. Smith

     

     

     

    Kevin P. Smith
    General Counsel & Corporate Secretary,
    Executive Vice President, Business Development
     

     


    Get the next $INGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INGN

    DatePrice TargetRatingAnalyst
    6/16/2025$14.00Buy
    B. Riley Securities
    5/22/2025$12.00Hold → Buy
    Needham
    2/15/2024Mkt Perform → Outperform
    William Blair
    8/8/2023$15.00 → $8.00Overweight → Neutral
    JP Morgan
    7/14/2023Buy → Hold
    Needham
    1/17/2023Outperform → Mkt Perform
    William Blair
    12/9/2021$47.00Hold → Buy
    Needham
    11/8/2021$70.00 → $40.00Hold
    Stifel
    More analyst ratings

    $INGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Chief Accounting Officer Wright Mary E was granted 2,851 shares, converted options into 7,506 shares and covered exercise/tax liability with 3,408 shares, increasing direct ownership by 57% to 19,129 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/3/26 5:00:25 PM ET
    $INGN
    Industrial Specialties
    Health Care

    EVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M converted options into 25,017 shares, covered exercise/tax liability with 15,382 shares and was granted 3,603 shares, increasing direct ownership by 98% to 26,747 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/3/26 4:59:20 PM ET
    $INGN
    Industrial Specialties
    Health Care

    EVP, Bus Dev, GC & Sec Smith Kevin P. converted options into 14,005 shares, covered exercise/tax liability with 6,276 shares and was granted 1,500 shares, increasing direct ownership by 72% to 22,007 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/3/26 4:57:51 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that Kevin Smith, President and Chief Executive Officer, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 10:15 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-publi

    3/31/26 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Compensation Committee of Inogen's Board of Directors approved awards of restricted stock units as material inducement to Jason Richardson and Dominic Hulton entering into employment with the company to serve as its Chief Financial Officer and Chief Marketing Officer, respectively. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with Inogen

    3/30/26 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth

    Jason Richardson Named Chief Financial Officer, Succeeding Michael Bourque Dominic Hulton Named Chief Marketing Officer Corey Moritz Appointed Vice President, U.S. Business to Business Sales Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the following leadership appointments designed to accelerate the company's next phase of growth. Jason Richardson Appointed Chief Financial Officer Jason Richardson has been appointed Chief Financial Officer, effective April 6, 2026. Mr. Richardson succeeds Michael Bourque, who will step down from his role as Chief Financial Officer on that date. M

    3/30/26 4:00:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    SEC Filings

    View All

    Inogen Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Inogen Inc (0001294133) (Filer)

    3/30/26 5:32:03 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Inogen Inc

    SCHEDULE 13G/A - Inogen Inc (0001294133) (Subject)

    3/27/26 9:55:41 AM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form S-8 filed by Inogen Inc

    S-8 - Inogen Inc (0001294133) (Filer)

    2/27/26 4:33:26 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:42:36 PM ET
    $INGN
    Industrial Specialties
    Health Care

    CEO and President Smith Kevin Raymond Merrill was granted 55,475 shares, converted options into 28,333 shares, covered exercise/tax liability with 39,797 shares and bought $100,245 worth of shares (11,709 units at $8.56), increasing direct ownership by 383% to 70,274 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:41:11 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Inogen with a new price target

    B. Riley Securities initiated coverage of Inogen with a rating of Buy and set a new price target of $14.00

    6/16/25 7:50:27 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen upgraded by Needham with a new price target

    Needham upgraded Inogen from Hold to Buy and set a new price target of $12.00

    5/22/25 8:16:14 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen upgraded by William Blair

    William Blair upgraded Inogen from Mkt Perform to Outperform

    2/15/24 6:28:38 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Leadership Updates

    Live Leadership Updates

    View All

    Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth

    Jason Richardson Named Chief Financial Officer, Succeeding Michael Bourque Dominic Hulton Named Chief Marketing Officer Corey Moritz Appointed Vice President, U.S. Business to Business Sales Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the following leadership appointments designed to accelerate the company's next phase of growth. Jason Richardson Appointed Chief Financial Officer Jason Richardson has been appointed Chief Financial Officer, effective April 6, 2026. Mr. Richardson succeeds Michael Bourque, who will step down from his role as Chief Financial Officer on that date. M

    3/30/26 4:00:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces the Appointment of Naga Rameswamy as Chief Technology Officer

    Inogen, Inc. (Nasdaq: INGN), a leading medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms. "Naga's deep background in digital health and connected device innovation makes him an ideal fit for Inogen as we continue to expand our technology leadership," said Kevin Smith, President and Chief Executive Officer of Inogen, "His ability to integrate software, data, and devices to improve user experiences will be instrume

    9/25/25 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    2/3/25 4:00:00 PM ET
    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $INGN
    Financials

    Live finance-specific insights

    View All

    Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook

    Delivered full year revenue growth of approximately 4% Significantly improved profitability with 2025 net loss of $22.7 million and positive adjusted EBITDA of $2.7 million Well-positioned to accelerate expected 2026 revenue growth and profitability Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year. "In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundam

    2/24/26 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025

    Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced preliminary, unaudited revenue results for the quarter and year ended December 31, 2025. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2025 to be approximately $82 million, representing year-over-year growth of approximately 2%. Full year 2025 total preliminary, unaudited revenue is expected to be approximately $349 million, representing year-over-year growth of approximately 4%. For the full year 2025, the Com

    1/12/26 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Third Quarter 2025 Financial Results

    Delivered seventh consecutive quarter of mid-single-digit revenue growth Reiterating full-year revenue guidance Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2025. Recent Highlights $92.4 million revenue, a year-over-year increase of 4.0%, marking the seventh consecutive quarter of mid-single-digit percentage growth GAAP net loss of $5.3 million and adjusted net loss of $0.5 million compared to prior year GAAP net loss of $6.0 million and adjusted net loss of $2.6 million $2.3 million adjusted EBITDA, the third consecutive quart

    11/5/25 7:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inogen Inc

    SC 13G/A - Inogen Inc (0001294133) (Subject)

    11/14/24 11:12:09 AM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Inogen Inc

    SC 13G - Inogen Inc (0001294133) (Subject)

    4/23/24 8:25:34 PM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Inogen Inc (Amendment)

    SC 13G/A - Inogen Inc (0001294133) (Subject)

    2/14/24 4:00:17 PM ET
    $INGN
    Industrial Specialties
    Health Care